You have printed or saved this information from www.HorizonNB.ca, the website for the Horizon Health Network
Infections
Infections
VE303-002: A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection
The purpose of this study is to see how safe and effective our study drug is, compared to a placebo (a capsule containing no active drug), at keepingC. difficile infection(CDI) from coming back in people who have recovered from an episode of CDI.
- Condition: C. difficile infection
- Website: NCT03788434
- Sponsor: Vedanta
- Location: The Moncton Hospital
- Horizon Principal Investigator: Dr. Dan Smyth
- To participate, call the research coordinator at: 506-857-5821 and refer to study file #100073
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with RecurrentClostridium difficileInfection
The purpose of this study is to learn about the safety of RBX2660 in patients with recurrent CDI.
- Condition: C. difficile infection
- Website: NCT03931941
- Sponsor: Rebiotix Inc.
- Location: The Moncton Hospital
- Horizon Principal Investigator: Dr. Dan Smyth
- To participate, call the research coordinator at: 506-857-5821 and refer to study file #100347
A 3-month research study of an investigational treatment forClostridium difficileInfection (CDI) to find out how effective and safe the study antibiotic (ridinilazole) is in treating CDI compared to a current antibiotic, vancomycin.
In this study, we will assess how safe ridinilazole is and how well it works at treating your CDI and stopping it from returning over a period of 3 months. The study will compare ridinilazole to vancomycin, which is an existing antibiotic that is marketed in Canada (approved for sale) and often used to treat CDI.
- Condition: C. difficile infection
- Website: NCT03595566
- Sponsor: Summit (Oxford) Limited
- Location: The Moncton Hospital
- Horizon Principal Investigator: Dr. Dan Smyth
- To participate, call the research coordinator at: 506-857-5821 and refer to study file #100500
ECOSPOR IV: An Open-Label Extension of Study Seres-012 and Open-Label Program for Evaluation SER-109 in Adult Subjects with Recurrent Clostridioides Difficile Infection (RCDI)
The purpose of this study is to see how safe and tolerable SER-109 is in keeping Clostridioides difficile infection (CDI) from coming back in people who have recovered from at least a first recurrence of CDI.
- Condition: C. difficile infection
- Website: NCT03183141
- Sponsor: Seres Therapeutics, Inc.
- Location: The Moncton Hospital
- Horizon Principal Investigator: Dr. Dan Smyth
- To participate, call the research coordinator at: 506-857-5821 and refer to study file #101244